Roth Capital Affirms BioBlast Pharma (ORPN) at 'Buy'; Sees Trehalose Plan Heading in Right Direction
Tweet Send to a Friend
Roth Capital affirms BioBlast Pharma (Nasdaq: ORPN) with a Buy rating and $15 price target following Q2 results released earlier ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
